Skip to main navigation
  • DEFLATEHAE.COM
  • Investors & News
  • Careers
  • Contact
Pharvaris N.V. homepage
  • Disease Focus
  • Community Commitment
  • Scientific Approach
    • Our Science
    • Pipeline
  • Scientific Publications
  • About Pharvaris
Pharvaris N.V. homepage
  • Disease Focus
  • Community Commitment
  • Scientific Approach
    • Our Science
    • Pipeline
  • Scientific Publications
  • About Pharvaris
  • DEFLATEHAE.COM
  • Investors & News
  • Careers
  • Contact

Event Details

Investor Menu

IR Nav

  • Overview
  • News & Events
    News Releases Events Publications
  • Financials
    SEC Filings Quarterly Results
  • Stock
    Stock Performance Analyst Coverage
  • Corporate Governance
    Governance Documents Leadership Board of Directors Committee Composition
  • Resources
    Investor FAQs Contact Us Email Alerts

ACAAI Annual Scientific Meeting 2022

Nov 10 - Nov 14, 2022

Supporting Materials

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks 818.4 KB
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist 937.4 KB
Pharvaris N.V.

©2026 Pharvaris N.V. © All Rights Reserved

Menu
  • Privacy Policy
  • Clinical Trial Privacy Notice
  • Global Privacy Laws
  • Terms of Use
CONTACT US
FOLLOW US